Access cutting-edge wet amd treatment through this clinical trial at a research site in Phoenix. Study-provided care at no cost to qualified participants.
Access wet amd specialists in Phoenix at no cost
This study follows strict safety protocols and ethical guidelines
All study-related wet amd treatment provided free
ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-vascular endothelial growth factor (anti-VEGF)
Sponsor: AbbVie
Check if you qualify for this wet amd clinical trial in Phoenix, AZ
If you're searching for wet amd treatment options in Phoenix, AZ, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Phoenix research site is actively enrolling participants for this clinical trial. You'll receive care from experienced wet amd specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.